Relationship between the efficacy of immunotherapy and characteristics of specific tumor mutation genes in non-small cell lung cancer patients.

The mutation of KRAS gene in tumor tissues is an independent predictor of the long-term benefit of immunotherapy, and the predictive ability is better.